NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness.
Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively. Compared with the same period in 2022, revenue increased by $3,211,558, due to the inclusion of the revenues of Phenix Bio Inc., which was acquired on March 15, 2023. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang hospitals, that were held for sale, were accounted for separately.
For the six months ended June 30, 2023, and 2022, The company achieved gross margins 52% and 15%, respectively, reflecting the high margins for the herbal supplements sold by Phenix Bio Inc..
The Company also reported changes in its cash position and working capital. On June 30, 2023, BIMI had cash of $1,931,744 and positive working capital of $6,604,643 as compared to cash of $2,336,636 and negative working capital of $326,672 on December 31, 2022.
"We are delighted with the initial success achieved by Phenix Bio Inc.", said Mr. Tiewei Song, the CEO of BIMI International Medical Inc.
About BIMI International Medical Inc.
BIMI International Medical Inc. is a healthcare products and services provider, offering a broad range of healthcare products and related services and operates five private hospitals in China. For more information, please visit .
Safe Harbor Statement
Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company's ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of COVID-19, the demand for the Company's products and services in the People's Republic of China, the continued positive results of the recently acquired Phenix Bio subsidiary, general economic conditions and other risk factors detailed in the Company's annual report and other filings with the United States Securities and Exchange Commission.
Investor Relations Contact
Investor Relations Department of BIMI International Medical Inc.
Email: vinson@usbimi.com
Tel: +1 949 981 6274
紐約，2023年11月27日（GLOBE NEWSWIRE）——領先的醫療解決方案提供商 BIMI International Medical Inc.（“公司”）今天公佈了截至 2023 年 6 月 30 日的三個月財務業績。該公司報告稱，毛利率大幅增加，這凸顯了其業務戰略和運營效率的持續成功。
截至2023年6月30日和2022年6月30日的六個月中，收入分別爲8,755,303美元和5,543,745美元。與2022年同期相比，收入增加了3,211,558美元，這是由於納入了2023年3月15日收購的Phenix Bio Inc. 的收入。待售的中山、強生、歐亞和民康醫院的收入分別入賬。
在截至2023年6月30日和2022年6月30日的六個月中，該公司分別實現了52％和15％的毛利率，這反映了Phenix Bio Inc.銷售的草藥補充劑的高利潤率。
該公司還報告了其現金狀況和營運資金的變化。2023年6月30日，BIMI的現金爲1,931,744美元，正營運資金爲6,604,643美元，而2022年12月31日的現金爲2,336,636美元，負營運資金爲326,672美元。
必米國際醫療公司首席執行官宋鐵偉說：“我們對Phenix Bio Inc. 取得的初步成功感到高興。”
關於 BIMI 國際醫療公司
BIMI International Medical Inc. 是一家醫療保健產品和服務提供商，提供廣泛的醫療產品和相關服務，並在中國經營五傢俬立醫院。欲了解更多信息，請訪問。
安全港聲明
本新聞稿中討論的某些事項是前瞻性陳述，涉及許多風險和不確定性，包括但不限於公司實現盈利經營的能力、繼續作爲持續經營企業經營的能力、繼續滿足納斯達克持續上市要求的能力、COVID-19 利差的影響、中華人民共和國對公司產品和服務的需求、最近收購的Phenix Bio子公司的持續積極業績，經濟的公司年度報告和向美國證券交易委員會提交的其他文件中詳述的情況和其他風險因素。
投資者關係聯繫人
BIMI 國際醫療公司投資者關係部
電子郵件：vinson@usbimi.com
電話：+1 949 981 6274
